PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-1.47%
Negative net income growth while CRVO stands at 52.71%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
-1.12%
Negative yoy D&A while CRVO is 0.00%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
11.01%
Deferred tax of 11.01% while CRVO is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
20.13%
SBC growth while CRVO is negative at -31.07%. John Neff would see competitor possibly controlling share issuance more tightly.
171.56%
Less working capital growth vs. CRVO's 876.21%, indicating potentially more efficient day-to-day cash usage. David Dodd would confirm no negative impact on revenue.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
36.25%
Lower AP growth vs. CRVO's 979.26%, indicating prompt payments. David Dodd would confirm no lost opportunity in interest-free credit if expansions are underfunded.
60.10%
Lower 'other working capital' growth vs. CRVO's 708.97%. David Dodd would see fewer unexpected short-term demands on cash.
20.13%
Some yoy increase while CRVO is negative at -98.98%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
23.86%
Operating cash flow growth similar to CRVO's 24.16%. Walter Schloss would see parallel improvements or market conditions in cash generation.
-1272.99%
Negative yoy CapEx while CRVO is 0.00%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1272.99%
We reduce yoy invests while CRVO stands at 0.00%. Joel Greenblatt sees near-term liquidity advantage unless competitor’s expansions yield high returns.
-196.64%
We cut debt repayment yoy while CRVO is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
1193.74%
Issuance growth of 1193.74% while CRVO is zero at 0.00%. Bruce Berkowitz sees a mild dilution that must be justified by expansions or acquisitions vs. competitor’s stable share base.
No Data
No Data available this quarter, please select a different quarter.